StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.97−0.99 (-1.91%)

Close on Nov 18, 2026

Genmab A/S Receivables Related to Collaboration Agreements by Quarter

Receivables Related to Collaboration Agreements ($M)

Genmab A/S Receivables Related to Collaboration Agreements: $992M in Q3 2026.

Latest, Q3 2026
992
Period ended Sep 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q4 2025
Sources
4
Documents cited below

Where the Q3 2026 figure comes from

“|| Receivables related to collaboration agreements | $ | 992 | $ | 907”

Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Genmab A/S Receivables Related to Collaboration Agreements ($M), quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/collab-receivables

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?